演題詳細

一般口演 / Oral Session

一般口演 3 (Oral Session 3) :AML:再発・難治性AML

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第4会場 / Room No.4 (さっぽろ芸文館 3F 黎明)
座長・司会
市川 幹 (Motoshi Ichikawa):1
1:湘南東部総合病院・クリニック 血液・腫瘍内科
 
前へ戻る

WT1 reduction rate by induction therapy is correlate with the prognosis in patients with AML

演題番号 : OS-1-12

盛 暁生 (Akio Mori):1、泉山 康 (Koh Izumiyama):1、斎藤 誠 (Makoto Saitoh):1、入江 達郎 (Tatsuro Irie):1、田中 雅則 (Masanori Tanaka):1、森岡 正信 (Masanobu Morioka):1

1:Department of Hematology, Medicine, Aiiku Hospital, Sapporo, Japan

 

Purpose: This study investigated the clinical value of monitoring peripheral blood WT1 mRNA levels in de novo acute myeloid leukemia (AML) patients. Patients and Methods: We evaluated 20 newly diagnosed and determined WT1 levels at diagnosis and after induction therapy de novo AML patients, retrospectively. Results: The median age was 60 years, and the median follow-up period was 17.5 months. No correlation was found between WT1 levels and age, FAB type and karyotype at diagnosis. Although WT1 levels at diagnosis seemed to be correlated with JALSG scoring system, there was no statistic significance (Good v.s. Intermediate v.s. Poor= 26533 v.s. 99681 v.s. 366333; p= 0.28). WT1 levels at diagnosis was not associated with the prognosis. However, overall survival of the patients with WT1 reduction rate by induction therapy less than 10-1 was significantly higher than that of the patients with WT1 reduction rate more than 10-1 (100% v.s. 0%; p<0.0001). All 15 patients with WT1 reduction rate by induction therapy less than 10-1 achieved CR by one course of induction therapy and survived with relapse-free. Within 5 patients with WT1 reduction rate more than 10-1, two patients achieved CR by one course of induction therapy, one with 2 courses, one with 3 courses, and one did not achieved CR. Even 4 patients who achieved CR, all of them relapsed and died. Conclusion: These results suggested that WT1 reduction rate by induction therapy was correlate with the prognosis in patients with de novo AML.

前へ戻る